Deprecated: Function jetpack_form_register_pattern is deprecated since version jetpack-13.4! Use Automattic\Jetpack\Forms\ContactForm\Util::register_pattern instead. in /var/www/html/wp-includes/functions.php on line 6031 Warning: Cannot modify header information - headers already sent by (output started at /var/www/html/wp-includes/functions.php:6031) in /var/www/html/wp-includes/rest-api/class-wp-rest-server.php on line 1794 {"id":9146,"date":"2022-06-28T15:53:00","date_gmt":"2022-06-28T12:53:00","guid":{"rendered":"https:\/\/inews24.eu\/?p=9146"},"modified":"2022-07-25T15:56:23","modified_gmt":"2022-07-25T12:56:23","slug":"eza-iesaka-registret-novavax-covid-19-vakcinu-nuvaxovid-pusaudziem-vecuma-no-12-lidz-17-gadiem","status":"publish","type":"post","link":"https:\/\/inews24.eu\/eza-iesaka-registret-novavax-covid-19-vakcinu-nuvaxovid-pusaudziem-vecuma-no-12-lidz-17-gadiem\/","title":{"rendered":"EZA iesaka re\u0123istr\u0113t Novavax Covid-19\u00a0vakc\u012bnu\u00a0\u201cNuvaxovid\u201d pusaud\u017eiem vecum\u0101 no 12 l\u012bdz 17 gadiem\u00a0"},"content":{"rendered":"\n

Pusaud\u017eiem vakc\u012bna lietojama t\u0101pat k\u0101 pieaugu\u0161ajiem \u2013 divu muskul\u012b veiktu injekciju veid\u0101 ar 3 ned\u0113\u013cu interv\u0101lu.<\/p>\n\n\n\n

\u0160obr\u012bd v\u0113l ir nepiecie\u0161ams sa\u0146emt Eiropas Komisijas l\u0113mumu par vakc\u012bnas apstiprin\u0101\u0161anu lieto\u0161anai pusaud\u017eiem<\/strong>, kas<\/strong> \u013cau<\/strong>s<\/strong> \u0161o vakc\u012bnu iek\u013caut<\/strong> Eiropas Savien\u012bbas <\/strong>(ES<\/strong>)<\/strong> \u012bstenotaj\u0101s vakcin\u0101cijas kampa\u0146\u0101s<\/strong>pusaud\u017eiem.<\/strong><\/p>\n\n\n\n

Saska\u0146\u0101 ar EZA Pediatrisk\u0101s komitejas (PDCO) apstiprin\u0101to vakc\u012bnas pediatrisk\u0101s izp\u0113tes pl\u0101nu (PIP) tiek veikts galvenais p\u0113t\u012bjums, kur\u0101 piedal\u0101s vair\u0101k nek\u0101 2200 b\u0113rnu vecum\u0101 no 12 l\u012bdz 17 gadiem.<\/p>\n\n\n\n

P\u0113t\u012bjums liecina, ka im\u016bn\u0101 atbilde pret vakc\u012bnu \u201cNuvaxovid\u201dpusaud\u017eiem, noteikta k\u0101 antivielu l\u012bmenis pret SARS-CoV-2 v\u012brusu, ir sal\u012bdzin\u0101ma ar im\u016bno atbildi gados jauniem pieaugu\u0161ajiem vecum\u0101 no 18 l\u012bdz 25 gadiem (kuri piedal\u012bj\u0101s galvenaj\u0101 p\u0113t\u012bjum\u0101 vakc\u012bnas efektivit\u0101tes izv\u0113rt\u0113\u0161anai pieaugu\u0161ajiem). P\u0113t\u012bjums tika veikts laik\u0101, kad domin\u0113ja SARS-CoV-2 delta paveids, un tas liecin\u0101ja, ka vakc\u012bnas efektivit\u0101te Covid-19 nov\u0113r\u0161an\u0101 bija gandr\u012bz 80 %. Se\u0161i no 1205 pusaud\u017eiem, kuri sa\u0146\u0113ma vakc\u012bnu \u201cNuvaxovid\u201d, saslima ar Covid-19 sal\u012bdzin\u0101jum\u0101 ar 14 no 594 pusaud\u017eiem, kuri sa\u0146\u0113ma placebo (ne\u012bstu injekciju). CHMP uzskat\u012bja, ka \u0161ie rezult\u0101ti atbilst rezult\u0101tiem, kas nov\u0113roti pieaugu\u0161ajiem.<\/p>\n\n\n\n

Bie\u017e\u0101k\u0101s pusaud\u017eiem nov\u0113rot\u0101s blakuspar\u0101d\u012bbas vairum\u0101 gad\u012bjumu ir l\u012bdz\u012bgas t\u0101m, kas nov\u0113rotas person\u0101m no 18 gadu vecuma. T\u0101s ietver jut\u012bgumu, s\u0101pes, aps\u0101rtumu un piet\u016bkumu injekcijas viet\u0101, galvass\u0101pes, musku\u013cu un loc\u012btavu s\u0101pes, nogurumu, visp\u0101r\u0113ji sliktu pa\u0161saj\u016btu, sliktu d\u016b\u0161u vai vem\u0161anu, un drudzi. Pusaud\u017eiem drudzis tiek nov\u0113rots bie\u017e\u0101k nek\u0101 pieaugu\u0161ajiem. \u0160\u012bs blakuspar\u0101d\u012bbas parasti ir vieglas vai vid\u0113ji smagas un mazin\u0101s p\u0101ris dienu laik\u0101 p\u0113c vakcin\u0101cijas.<\/p>\n\n\n\n

T\u0101d\u0113\u013c CHMP uzskata, ka vakc\u012bnas \u201cNuvaxovid\u201d sniegtie ieguvumi pusaud\u017eiem vecum\u0101 no 12 l\u012bdz 17 gadiem atsver t\u0101s riskus.<\/p>\n\n\n\n

Vakc\u012bnas dro\u0161ums un efektivit\u0101te pusaud\u017eiem un pieaugu\u0161ajiem joproj\u0101m tiks cie\u0161i uzraudz\u012bti, vakc\u012bnu izmantojot vakcin\u0101cijas kampa\u0146\u0101s ES dal\u012bbvalst\u012bs. Tas tiks veikts ar ES z\u0101\u013cu dro\u0161uma uzraudz\u012bbas (farmakovigilances)sist\u0113mas pal\u012bdz\u012bbu, k\u0101 ar\u012b ar uz\u0146\u0113muma un Eiropas iest\u0101\u017eu pa\u0161reiz norito\u0161o un papildus p\u0113t\u012bjumu pal\u012bdz\u012bbu.<\/p>\n\n\n\n

K\u0101 darbojas <\/strong>vakc\u012bna \u201c<\/strong>Nuvaxovid<\/strong>\u201d<\/strong>?<\/strong><\/p>\n\n\n\n

Vakc\u012bna \u201cNuvaxovid\u201d sagatavo organismu aizsardz\u012bbai pret Covid-19. Vakc\u012bnas pamat\u0101 ir olbaltumvielas, kas satur laboratoriskos apst\u0101k\u013cos rad\u012btas koronav\u012brusa sast\u0101v\u0101 eso\u0161as p\u012b\u0137a prote\u012bna (S prote\u012bna) da\u013ci\u0146as. Vakc\u012bna satur ar\u012b \u201cadjuvantu\u201d \u2013 vielu, kas pal\u012bdz pastiprin\u0101t im\u016bno atbildi pret vakc\u012bnu.<\/p>\n\n\n\n

P\u0113c vakc\u012bnas ievad\u012b\u0161anas cilv\u0113ka im\u016bn\u0101 sist\u0113ma atpaz\u012bs prote\u012bna da\u013ci\u0146as k\u0101 organismam nepiedero\u0161as un uzs\u0101ks dab\u012bg\u0101s aizsargreakcijas (antivielu un T \u0161\u016bnu) veido\u0161anu pret t\u0101m. Ja vakcin\u0113t\u0101 persona v\u0113l\u0101k saskarsies ar SARS-CoV-2 v\u012brusu, im\u016bn\u0101 sist\u0113ma atpaz\u012bs uz v\u012brusa eso\u0161o p\u012b\u0137a prote\u012bnu un b\u016bs gatava pret to c\u012bn\u012bties. Antivielas un im\u016bn\u0101s \u0161\u016bnas kop\u0101 var aizsarg\u0101t pret Covid-19, izn\u012bcinot v\u012brusu, nov\u0113r\u0161ot t\u0101 iek\u013c\u016b\u0161anu organisma \u0161\u016bn\u0101s un izn\u012bcinot infic\u0113t\u0101s \u0161\u016bnas.<\/p>\n\n\n\n

Vakc\u012bna \u201cNuvaxovid\u201d tiek ievad\u012bta divu injekciju veid\u0101 aug\u0161delma muskul\u012b ar tr\u012bs ned\u0113\u013cu starplaiku.<\/p>\n\n\n\n

Kur ir pieejama inform\u0101cija?<\/strong><\/p>\n\n\n\n

Produkta inform\u0101cija vakc\u012bnai \u201cNuvaxovid\u201d ietver vesel\u012bbas apr\u016bpes profesion\u0101\u013ciem paredz\u0113to z\u0101\u013cu aprakstu, lieto\u0161anas instrukciju sabiedr\u012bbai un inform\u0101ciju par re\u0123istr\u0101cijas apliec\u012bbas nosac\u012bjumiem.<\/p>\n\n\n\n

Nov\u0113rt\u0113juma zi\u0146ojums, ietverot EZA veikto Nuvaxovidizv\u0113rt\u0113jumu, k\u0101 ar\u012b pilns riska p\u0101rvald\u012bbas pl\u0101ns tiks public\u0113ts da\u017eu dienu laik\u0101. Kl\u012bnisk\u0101 p\u0113t\u012bjuma dati, ko uz\u0146\u0113mums iesniedzis re\u0123istr\u0101cijas apliec\u012bbas sa\u0146em\u0161anai, noteiktaj\u0101 laik\u0101 tiks public\u0113ti EZA kl\u012bnisko datu t\u012bmek\u013ca vietn\u0113<\/a>.<\/p>\n\n\n\n

Pla\u0161\u0101ka inform\u0101cija pieejama p\u0101rskat\u0101 par \u0161o vakc\u012bnu<\/a>, tostarp vakc\u012bnas ieguvumu un risku apraksts un EZA ieteikuma pamatojums vakc\u012bnas re\u0123istr\u0101cijai ES.<\/p>\n\n\n\n

Vakc\u012bnas \u201c<\/strong>Nuvaxovid<\/strong>\u201d<\/strong> dro\u0161uma uzraudz\u012bba<\/strong><\/p>\n\n\n\n

Saska\u0146\u0101 ar ES Covid-19 vakc\u012bnu dro\u0161uma uzraudz\u012bbas pl\u0101nu<\/a>vakc\u012bna \u201cNuvaxovid\u201d tiek cie\u0161i uzraudz\u012bta un pak\u013cauta vair\u0101kiem konkr\u0113ti Covid-19 vakc\u012bn\u0101m piem\u0113rojamiem pas\u0101kumiem. Lai gan kl\u012bnisko p\u0113t\u012bjumu ietvaros Covid-19 vakc\u012bnas ir sa\u0146\u0113mis liels cilv\u0113ku skaits, noteiktas blakuspar\u0101d\u012bbas var tikt nov\u0113rotas tikai tad, kad vakcin\u0113ti tiek miljoniem cilv\u0113ku. Turkl\u0101t ES iest\u0101\u017eu koordin\u0113tie neatkar\u012bgie Covid-19 vakc\u012bnu p\u0113t\u012bjumi<\/a> sniegs pla\u0161\u0101ku inform\u0101ciju par vakc\u012bnas ilgtermi\u0146a dro\u0161umu un ieguvumiem visp\u0101r\u0113j\u0101 sabiedr\u012bb\u0101.<\/p>\n\n\n\n

\u0160ie pas\u0101kumi \u013cauj normat\u012bv\u0101 regul\u0113juma nodro\u0161in\u0101t\u0101jiem \u0101tri izv\u0113rt\u0113t jaun\u0101kos datus no da\u017e\u0101diem avotiem un veikt jebk\u0101das nepiecie\u0161am\u0101s regul\u0113jo\u0161\u0101s darb\u012bbas sabiedr\u012bbas vesel\u012bbas aizsardz\u012bbai.<\/p>\n\n\n\n

EZA zin\u0101tniskaj\u0101s komitej\u0101s un darba grup\u0101s piedal\u0101s ar\u012b Latvijas Z\u0101\u013cu valsts a\u0123ent\u016bras speci\u0101listi.<\/p>\n","protected":false},"excerpt":{"rendered":"